Management of Colorectal Cancer Liver Metastases
- PMID: 38275861
- PMCID: PMC10814437
- DOI: 10.3390/cancers16020420
Management of Colorectal Cancer Liver Metastases
Abstract
Ivey et al [...].
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Tsilimigras D.I., Ntanasis-Stathopoulos I., Bagante F., Moris D., Cloyd J., Spartalis E., Pawlik T.M. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Surg. Oncol. 2018;27:280–288. doi: 10.1016/j.suronc.2018.05.012. - DOI - PubMed
-
- Kawaguchi Y., Kopetz S., Newhook T.E., De Bellis M., Chun Y.S., Tzeng C.-W.D., Aloia T.A., Vauthey J.-N. Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. Clin. Cancer Res. 2019;25:5843–5851. doi: 10.1158/1078-0432.CCR-19-0863. - DOI - PMC - PubMed
-
- Aquina C.T., Brown Z.J., Beane J.D., Ejaz A., Cloyd J.M., Tsung A., Adam M.O., Pawlik T.M., Kim A.C. Disparities in Care Access to Liver-Directed Therapy Among Medicare Beneficiaries with Colorectal Cancer Liver Metastasis. Ann. Surg. Oncol. 2023;30:335–344. doi: 10.1245/s10434-022-12513-0. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
